PKCδ is generally known as a pro-apoptotic and anti-proliferative enzyme in human prostate cancer cells.

Here, we investigated the role of PKCδ on the growth of PC-3 human prostate cancer cells in vivo and in vitro.

We found that sustained treatment with a specific PKCδ activator (Ψδ receptor for active C kinase, ΨδRACK) increased growth of PC-3 xenografts. There was increased levels of HIF-1α, vascular endothelial growth factor and CD31-positive cells in PC-3 xenografts, representative of increased tumor angiogenesis. Mechanistically, PKCδ activation increased the levels of reactive oxygen species (ROS) by binding to and phosphorylating NADPH oxidase, which induced its activity. Also, PKCδ-induced activation of NADPH oxidase increased the level of HIF-1α.

Our results using tumors from the PC-3 xenograft model suggest that PKCδ activation increases angiogenic activity in androgen-independent PC-3 prostate cancer cells by increasing NADPH oxidase activity and HIF-1α levels and thus may partly be responsible for increased angiogenesis in advanced prostate cancer. Prostate © 2010 Wiley-Liss, Inc.

PMID: 21104994 [PubMed - as supplied by publisher] Source: National Library of Medicine.